This is a summary of the European public assessment report (EPAR) for Kengrexal. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kengrexal. For practical information about using Kengrexal, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
Therapeutic Area (MeSH)
N/AATC Code
B01
ATC Item
抗血栓形成药
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| cangrelor | N/A | Cangrelor |
EMA Name
Kengrexal
Medicine Name
Kengrexal
Aliases
N/ANo risk management plan link.
